Twitter | Search | |
Mohamed E. Salem, MD
GI Medical Oncologist
492
Tweets
123
Following
409
Followers
Tweets
Mohamed E. Salem, MD 42m
How to better select for Anti-EGFR therapy. Beyond RAS/BRAF wild type status. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based
Reply Retweet Like
Mohamed E. Salem, MD retweeted
Richard Dunne 9h
ORR of 33% & 33% in MSI-H who have received 2 or more lines of tx, 1 or more lines, respectively in this single arm phase 2-not a far cry from 40% ORR seen in landmark trial in 2015 looks like may settle in as 2nd line tx in MSI-H CFC
Reply Retweet Like
Mohamed E. Salem, MD retweeted
JAMA Oncology 9h
Reply Retweet Like
Mohamed E. Salem, MD retweeted
J Clinical Oncology Nov 7
Coming soon: the handle is getting an update in December and will bring our family of ASCO journals together plus ASCO Daily News, and the Educational Book.
Reply Retweet Like
Mohamed E. Salem, MD retweeted
Philippe Aftimos, MD Nov 16
Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer
Reply Retweet Like
Mohamed E. Salem, MD retweeted
JAMA Oncology Nov 8
Viewpoint highlights neuroendocrine tumors are rising rapidly in incidence, now 2nd most common GI cancer after colorectal, but research & treatments have been limited – time to dedicate more effort to advancing field & options for pts
Reply Retweet Like
Mohamed E. Salem, MD retweeted
J Clinical Oncology Nov 8
Compared with gefitinib alone, gefitinib + chemotherapy improves PFS in people with untreated advanced NSCLC with EGFR mutations
Reply Retweet Like
Mohamed E. Salem, MD Nov 7
I greatly enjoyed your talk . Great job and insights!! And thanks to team for the overwhelming hospitality and hosting a wonderful meeting!
Reply Retweet Like
Mohamed E. Salem, MD Nov 6
Replying to @RachelRiechelm2
Big congratulations!!
Reply Retweet Like
Mohamed E. Salem, MD retweeted
Nathan A. Pennell MD, PhD Nov 4
I realize this is late in the season, but if any senior heme-onc fellows or junior faculty are still looking for a faculty position in thoracic oncology for 2020 please reach out to me!
Reply Retweet Like
Mohamed E. Salem, MD retweeted
SWOG Cancer Research Network Nov 4
Hey members: If you have the seed for a great cancer trial idea, apply for this funding by Dec. 1. SEED Fund grants have led to heavy-hitting trials in our treatment portfolio and our prevention and care improvement portfolio.
Reply Retweet Like
Mohamed E. Salem, MD Nov 1
It was a pleasure and honor to participate in . Great science and meeting and amazing country and people! Looking forward to
Reply Retweet Like
Mohamed E. Salem, MD Nov 1
Congratulations on the new position! you got yourself a great win and excellent Doc!
Reply Retweet Like
Mohamed E. Salem, MD retweeted
ASCO Nov 1
Members: Voting for the 2020 ASCO Election is now open! Make your voice heard – vote now
Reply Retweet Like
Mohamed E. Salem, MD retweeted
ASCO Nov 1
Please spread the word about this upcoming event at HQ on the basics of cancer. We hope to see you November 12!
Reply Retweet Like
Mohamed E. Salem, MD Oct 26
With Dr. Kazuhiro Yoshida (president of the 57th meeting), Mami Sakurai and Great collaboration, excellent meeting and overwhelming hospitality. Also amazing country and extremely kind people!!
Reply Retweet Like
Mohamed E. Salem, MD Oct 25
Replying to @oliviawriting
Thanks! It was great meeting you. Please keep in touch and looking forward to seeing you soon
Reply Retweet Like
Mohamed E. Salem, MD Oct 25
It was a great honor and pleasure to participate in this important meeting and collaboration. Thanks to and
Reply Retweet Like
Mohamed E. Salem, MD Oct 24
Agreed! It was an honor to be part of of such an outstanding session. Thank you . I enjoyed your talk about HIPEC and its utilization in . .
Reply Retweet Like
Mohamed E. Salem, MD Oct 24
Great dinner, outstanding company with great friends and colleagues
Reply Retweet Like